Literature DB >> 3169112

Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

G T McInnes1, M J Brodie.   

Abstract

The effects of two oxprenolol oral osmotic (OROS) delivery systems on heart rate and blood pressure before and during recovery from exercise at a predetermined load were examined in twelve patients with hypertension previously responding to beta-blocker monotherapy. Haemodynamic responses were attenuated during the 24 h after single and repeated (15 days') once daily administrations of 10/170 and 16/260 oxprenolol OROS. At 24 h after repeated doses, compared to placebo there were significant reductions in resting blood pressure and in heart rate immediately following exercise. Attenuation of heart rate after exercise was dose related but differences between the systems with respect to resting heart rate and blood pressure were inconsistent. Antihypertensive responses after repeated doses were greater than those after single doses. However, reductions in resting and exercise heart rates were consistently less on chronic therapy. This may reflect enhanced expression of the partial agonist activity of oxprenolol due to altered receptor sensitivity after prolonged beta-blockade. The plasma oxprenolol profiles after both systems indicated slow absorption and substantial concentrations were apparent 24 h after drug administration. These observations suggest that both oxprenolol OROS systems display sustained drug release and on once daily dosing provide 24 h beta-blockade and control of blood pressure at rest and following exercise.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3169112     DOI: 10.1007/bf00615225

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  Beta blockade in essential hypertension: an analysis of response to oxprenolol.

Authors:  D W Barritt; A J Marshall
Journal:  Br Heart J       Date:  1977-08

Review 3.  Adrenergic receptors in hypertension: radioligand binding studies.

Authors:  C Rosendorff; E Susanni; M L Hurwitz; F P Ross
Journal:  J Hypertens       Date:  1985-12       Impact factor: 4.844

Review 4.  The properties of beta-adrenoceptor antagonists.

Authors:  R G Shanks
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

5.  Descriptive data analysis: a concept between confirmatory and exploratory data analysis.

Authors:  K Abt
Journal:  Methods Inf Med       Date:  1987-04       Impact factor: 2.176

Review 6.  Which beta blocker?

Authors:  A Breckenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-02

7.  Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men.

Authors:  F H Leenen; C H Coenen; M Zonderland; A H Maas
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

8.  Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.

Authors:  A Racine-Poon; J Moppert
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

9.  Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

10.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

View more
  1 in total

1.  CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

Authors:  A L van Steveninck; M S Pieters; H C Schoemaker; D D Breimer; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.